Cornelia Liedtke

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. ncbi Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes
    Cornelia Liedtke
    Department of Gynecology and Obstetrics, University Hospital Muenster, Muenster, Germany
    Eur J Cancer 48:2066-74. 2012
  2. ncbi Caveolin-1 expression in benign and malignant lesions of the breast
    Cornelia Liedtke
    Department of Obstetrics and Gynecology, University of Munster, Albert Schweitzer Str, 33, 48149 Munster, Germany
    World J Surg Oncol 5:110. 2007
  3. ncbi A clinically relevant gene signature in triple negative and basal-like breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, Frankfurt, 60590, Germany
    Breast Cancer Res 13:R97. 2011
  4. ncbi Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression
    Christian Kersting
    Institute of Pathology, University of Muenster, Muenster, Germany
    Lab Invest 86:54-61. 2006
  5. ncbi The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
    Eberhard Korsching
    Institute of Pathology, University of Munster, Germany
    J Pathol 206:451-7. 2005
  6. ncbi Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
    Thomas Karn
    Department of Obstetrics and Gynecology, J W Goethe University, Frankfurt, Germany
    PLoS ONE 6:e28403. 2011
  7. ncbi Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
    Lars C Hanker
    Department of Gynecology and Obstetrics, University Medical Center Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538, Lubeck, Germany
    Breast Cancer Res Treat 137:407-16. 2013
  8. ncbi T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
    Achim Rody
    Department of Obstetrics and Gynecology, JW Goethe University, Theodor Stern Kai 7, Frankfurt, Germany
    Breast Cancer Res 11:R15. 2009
  9. ncbi Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
    Christian Kersting
    Institute of Pathology, University of Muenster, Muenster, Germany
    Lab Invest 84:582-7. 2004
  10. ncbi Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
    Thomas Karn
    Department of Obstetrics and Gynecology, JW Goethe University, Frankfurt, Germany
    Eur J Cancer 48:12-23. 2012

Detail Information

Publications11

  1. ncbi Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes
    Cornelia Liedtke
    Department of Gynecology and Obstetrics, University Hospital Muenster, Muenster, Germany
    Eur J Cancer 48:2066-74. 2012
    ..Molecular breast cancer subgroups show differences with regard to prognosis and response to chemotherapy. In vitro chemotherapy sensitivity and resistance assays (CSRAs) are a means to directly evaluate tumour cell response to a given drug...
  2. ncbi Caveolin-1 expression in benign and malignant lesions of the breast
    Cornelia Liedtke
    Department of Obstetrics and Gynecology, University of Munster, Albert Schweitzer Str, 33, 48149 Munster, Germany
    World J Surg Oncol 5:110. 2007
    ..abstract:..
  3. ncbi A clinically relevant gene signature in triple negative and basal-like breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, Frankfurt, 60590, Germany
    Breast Cancer Res 13:R97. 2011
    ..Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat this disease...
  4. ncbi Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression
    Christian Kersting
    Institute of Pathology, University of Muenster, Muenster, Germany
    Lab Invest 86:54-61. 2006
    ..The observed association between intron 1 amplification and overexpression of EGFR provides further insight into regulation mechanisms of EGFR overexpression...
  5. ncbi The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
    Eberhard Korsching
    Institute of Pathology, University of Munster, Germany
    J Pathol 206:451-7. 2005
    ..We therefore propose the alternative hypothesis that vimentin-expressing breast carcinomas may derive from breast progenitor cells with bilinear (glandular and myoepithelial) differentiation potential...
  6. ncbi Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
    Thomas Karn
    Department of Obstetrics and Gynecology, J W Goethe University, Frankfurt, Germany
    PLoS ONE 6:e28403. 2011
    ..The identification of prognostic signatures from TNBC cohorts was limited in the past due to small sample sizes...
  7. ncbi Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
    Lars C Hanker
    Department of Gynecology and Obstetrics, University Medical Center Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538, Lubeck, Germany
    Breast Cancer Res Treat 137:407-16. 2013
    ..This result underlines the importance of subtype-specific analyses and suggests a sequential multistep approach to developing and applying outcome predictors in the clinic...
  8. ncbi T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
    Achim Rody
    Department of Obstetrics and Gynecology, JW Goethe University, Theodor Stern Kai 7, Frankfurt, Germany
    Breast Cancer Res 11:R15. 2009
    ..However, specific lymphocytes might also promote tumor progression by shifting the cytokine milieu in the tumor...
  9. ncbi Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
    Christian Kersting
    Institute of Pathology, University of Muenster, Muenster, Germany
    Lab Invest 84:582-7. 2004
    ..7% of cases. However, since about 75% of cases with EGFR protein overexpression lack either of these amplifications, other expression regulating mechanisms must be considered...
  10. ncbi Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
    Thomas Karn
    Department of Obstetrics and Gynecology, JW Goethe University, Frankfurt, Germany
    Eur J Cancer 48:12-23. 2012
    ..Oestrogen (ER) and human epidermal growth factor receptor 2 (HER2) receptors are strongly bimodally expressed genes in breast cancer...
  11. ncbi Personalized treatment of early-stage breast cancer: present concepts and future directions
    Nadia Harbeck
    Breast Center, Department of Gynecology and Obstetrics, University Hospital Köln, Cologne, Germany
    Cancer Treat Rev 36:584-94. 2010
    ..It will also highlight how carefully molecular tests need to be methodologically and clinically validated before they can be applied for clinical decision making...